Translation Built for Regulatory Submission and Market Access
Our approach is built for submission environments, aligned with authority expectations.
Built for Submission Environments. Aligned with Authority Expectations.
When companies prepare documentation to commercialize a drug or medical device, every section must align with nationally mandated templates, harmonized terminology, and authority-specific formatting conventions.
From the EMA’s QRD template governing SmPC and PIL content to Health Canada Product Monographs, FDA Structured Product Labeling (SPL), and MDR technical documentation requirements, regulatory content follows predefined frameworks that cannot be altered.
Welo Life Sciences supports regulatory and market access teams with translation workflows designed for submission environments. Our approach combines linguistic precision, structured template alignment, and familiarity with country-specific authority expectations, so documentation progresses through review cycles without rework or delay.
Where Welo Life Sciences Fits
Regulatory and market access documentation sits at the intersection of scientific evidence, legal requirements, and national health policy. It must comply with defined section hierarchies, standardized headings, controlled terminology, and country-specific formatting constraints, whether a CTD Module 1 regional annex, a QRD-compliant product information set, or an MDR Annex II/III technical documentation package.
We deliver translations structured for regulatory review, not generic localization workflows. Our processes preserve section numbering, heading hierarchies, cross-references, and embedded regulatory statements, preventing the deviations that trigger authority questions, delay review timelines, or require resubmission.
Because when documentation sits on the critical path to approval, both linguistic precision and structural fidelity matter.
HOW WE SUPPORT REGULATORY AND MARKET ACCESS TEAMS
Coverage Across The Full Regulatory Lifecycle
From initial submission through post-approval maintenance, structured for the procedural environments your documentation lives in.
Translation and localization aligned with nationally mandated templates and authority-facing submission structures.
- QRD-compliant product information (SmPC, PIL, and labeling) for EMA centralized and decentralized procedures
- Health Canada Product Monographs and Swissmedic-compliant product information, Taiwan FDA, South Korea MFDS, and Register of Medicinal Products of Russia (РЛС)
- FDA Structured Product Labeling (SPL) content
- Medical device Instructions for Use aligned with MDR Annex I General Safety and Performance Requirements
Supporting documentation within structured submission frameworks, aligned with CP, DCP, MRP, and national procedure timelines.
- CTD/eCTD module documentation across all five modules
- Variations (Type IA, IB, II), renewals, and urgent safety restrictions
- MDR Annex II and III technical documentation for device submissions
- National-phase labeling adaptations coordinated with RMS/CMS timelines
Supporting documentation used in reimbursement, pricing, and payer review environments.
- HTA dossiers including NICE, G-BA, HAS, and AIFA submission formats
- Payer value dossiers and AMNOG-style benefit assessment documentation
- National reimbursement submissions and pricing applications
- Health authority responses, RFI translations, and query resolution documentation
Translation support aligned with ongoing regulatory change and multi-market label maintenance.
- Safety-related labeling variations and urgent safety restrictions
- Periodic Safety Update Reports (PSURs) and PSUR single assessments
- Multi-market labeling harmonization projects including post-PSUSA worksharing outcomes
- Controlled terminology updates aligned with MedDRA version changes
Why Regulatory Teams Trust Welo Life Sciences
Built around fixed procedural timelines
Submission windows, Day 120 responses, and RMS/CMS comment rounds do not move. Our workflows are designed to deliver within regulatory procedural clocks and not generic project timelines.
Accuracy aligned with authority templates
We translate within the structural frameworks regulators expect, reducing the risk of inconsistencies that trigger authority questions or labeling objections.
Compliance built into the workflow
Our quality framework supports terminology control, version traceability, and audit-ready documentation management. Content is delivered ready for authority-facing environments.
Secure, structured operations
Our secure digital environment supports controlled document handling, version control, and protection of sensitive regulatory documentation.
Cross-sector regulatory depth
Our teams understand the structural and regulatory nuances across pharmaceuticals, biologics, medical devices, and IVDs.
Built for lifecycle continuity
Approval is not the endpoint. We support ongoing variations, safety updates, harmonization initiatives, and multi-market labeling maintenance with the same structural precision applied to initial submissions.
